Trial Profile
Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics and Preliminary Efficacy of SC10914 in Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs SC 10914 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangxi Qingfeng Pharmaceutical
- 31 May 2020 Results (n=52; as of Jan 2020) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 25 Oct 2016 New trial record